key: cord-0970813-i05awado
authors: Zabaleta, Nerea; Dai, Wenlong; Bhatt, Urja; Hérate, Cécile; Maisonnasse, Pauline; Chichester, Jessica A.; Sanmiguel, Julio; Estelien, Reynette; Michalson, Kristofer T.; Diop, Cheikh; Maciorowski, Dawid; Dereuddre-Bosquet, Nathalie; Cavarelli, Mariangela; Gallouët, Anne-Sophie; Naninck, Thibaut; Kahlaoui, Nidhal; Lemaitre, Julien; Qi, Wenbin; Hudspeth, Elissa; Cucalon, Allison; Dyer, Cecilia D.; Pampena, M. Betina; Knox, James J.; LaRocque, Regina C.; Charles, Richelle C.; Li, Dan; Kim, Maya; Sheridan, Abigail; Storm, Nadia; Johnson, Rebecca I.; Feldman, Jared; Hauser, Blake M.; Contreras, Vanessa; Marlin, Romain; Tsong Fang, Raphaël Ho; Chapon, Catherine; van der Werf, Sylvie; Zinn, Eric; Ryan, Aisling; Kobayashi, Dione T.; Chauhan, Ruchi; McGlynn, Marion; Ryan, Edward T.; Schmidt, Aaron G.; Price, Brian; Honko, Anna; Griffiths, Anthony; Yaghmour, Sam; Hodge, Robert; Betts, Michael R.; Freeman, Mason W.; Wilson, James M.; Le Grand, Roger; Vandenberghe, Luk H.
title: An AAV-based, room-temperature stable, single dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates
date: 2021-08-07
journal: Cell Host Microbe
DOI: 10.1016/j.chom.2021.08.002
sha: c2041467514a66f8be5bcc2e938fe0b561518577
doc_id: 970813
cord_uid: i05awado

The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 million deaths. To contain the pandemic, there is a continued need for safe vaccines that provide durable protection at low and scalable doses and are easily delivered. Here, AAVCOVID-1, an adeno-associated viral (AAV), Spike gene-based vaccine candidate demonstrates potent immunogenicity in mouse and nonhuman primates following a single injection and confers complete protection from SARS-CoV-2 challenge in macaques. Peak neutralizing antibody titers are sustained at 1 year and complemented by functional memory T-cell responses. The AAVCOVID vector has no relevant pre-existing immunity in humans, does not elicit cross-reactivity to common AAVs used in gene therapy, and its persistence and expression wanes following injection. The single, low dose requirement, high yield manufacturability, and 1-month stability for storage at room-temperature may make this technology well-suited to support effective immunization campaigns for emerging pathogens on a global scale.

As public health programs race to vaccinate individuals with these early wave vaccines, some of the 97 limitations of the first-generation vaccines are becoming increasingly apparent, especially for distribution 98 in low-and middle-income countries. The cold chain storage requirement and reliance on more than one 99 injection to induce protective immunity are major limitations of some of the first-generation vaccines 100 Here, we interrogate the safety and immunogenicity of class of experimental vaccines that has previously 112 humoral and cellular immunogenicity following a single dose intramuscular injection in mice and 115 nonhuman primates to various viral pathogens (Li et Wild type AAV is a non-enveloped single stranded DNA dependoparvovirus with broad host range 122 including nonhuman and human primates. AAV is not known to cause disease, however antibodies 123 directed at many AAV serotypes are prevalent, suggesting it is endemic in human populations (Calcedo et helper. At harvest, yields for AC1 and AC3 were above 7 x 10 15 genome containing particles or genome 192 copies (gc). Subsequent purification included multiple tangential flow filtration (TFF), an ion-exchange 193 chromatography and a cesium chloride density gradient step to eventually recover between 21% and 26% 194 in the final drug substance. Of note, given the expedited nature of these studies, less than 2 weeks of 195 process development studies were performed to successfully adapt the existing scalable production 196 system to AAVrh32.33. 197 To interrogate the cold chain requirements for storage and transportation of AAVCOVID in liquid 198 formulation, toxicology grade AC1 product generated with the iCellis process was aliquoted (n=5) and 199 stored at different temperature conditions (-80⁰ C, 4⁰ C or 25⁰ C) for 4 and 12 weeks. Physical stability 200 was assessed by ddPCR for genomic titer ( Figure 1E ) and differential scanning fluorimetry (Pacouret et 201 al., 2017) for capsid integrity (Figures S1E and S1EF). Functional stability was measured in female 202 C57BL/6 via RBD-IgG ELISA ( Figure 1F ) and pseudovirus neutralization ( Figure 1G ) on serum 203 collected 3 weeks following single 10 11 gc dose IM immunization. Storage at 25⁰ C for 12 weeks led to 204 reduction of genomic titer, capsid instability and a loss of potency. AC1 was found stable in liquid 205 formulation at all temperature conditions for 1 month, and for at least 12 weeks at -80⁰ C and 4⁰ C 206 ( Figures 1E-1G and S1E-S1F). 207

The immunogenicity of AC1 and AC3 following a single injection at a low and high dose of 10 10 and 10 11 209 gc, respectively, in the gastrocnemius muscle was evaluated in 6-7-week-old C57BL/6 ( Figure 2) and 210 BALB/C ( Figures S2C-S2E ) mice of both genders. SARS-CoV-2 RBD-binding IgG antibody levels were 211 monitored by ELISA at regular intervals (Figures 2A and S2C ), as were neutralizing antibody levels 212 assayed using a SARS-CoV-2 Spike pseudotyped lentivirus (pseudovirus) inhibition-of-transduction 213 method ( Figures 2B and S2D) . 214 J o u r n a l P r e -p r o o f Dose-dependent potent binding and neutralizing responses from a single dose administration of AC1 or 215 AC3 that persisted for 6 months in C57Bl/6 (Figures 2A and 2B) . Overall, AC1 at high doses induced a 216 significantly higher level of RBD-binding and pseudovirus neutralizing antibody titers than AC3. Full 217 seroconversion was achieved for both AC1 doses and the high AC3 dose but was partial for AC3 at the 218 low dose (Figure 2A ). Immunogenicity was lower by 2-3-fold in males versus female mice 4 weeks after 219 vaccination for both candidates at high dose ( Figure 2C ), but no significant differences were found in 220 later timepoints (data not shown). Neutralizing antibody kinetics lagged by approximately a week to 221 stabilize after 4 weeks ( Figures 2B and S2A ). Across all candidates and timepoints, RBD-binding and 222 neutralizing titers showed modest correlation, and illustrated that AC1 achieved proportionally higher 223 levels of neutralizing antibody compared to AC3 ( Figure S2B ). Studies in BALB/c, confirmed the 224 findings in C57BL/6 mice, however overall had lower antibody titers. Distinct from C57BL/6 mice, at 225 low does AC1 and AC3 led to similar levels of RBD-binding titers ( Figures S2C-S2E ). Antibody 226 isotyping was analyzed to assess Th1/Th2 responses, this is an important measurement since dysregulated 227

Th2 responses have previously been associated with vaccine enhanced disease (Lee et al., 2020; Tseng et 228 al., 2012) . This analysis suggest a balanced Th1 response stimulated by AC1, yet a more Th2 skewed 229 AC3 response in BALB/c mice ( Figure S3A ). 230 Cellular responses were quantified by ELISPOT in splenocytes from low dose AC1 and AC3 immunized 231 C57BL/6 animals 6 weeks after vaccination. IFN- ELISPOT revealed a robust response against peptides 232 spanning the S1 subunit ( Figure 2D 

To qualitatively assess the immunogenicity of AAVCOVID in humans, rhesus macaque (n=2 per vaccine 240 candidate) were IM injected with 10 12 gc of AC1 and AC3 and monitored for now up to 1 year in an 241 ongoing study. Animals tolerated the vaccine dose well, with no temperature elevations or local 242 reactogenicity based on clinical examinations, complete blood counts and chemistry, or cytokine analysis 243 (data not shown). Regular phlebotomies were performed to assess RBD-binding, pseudovirus 244 neutralizing, and live SARS-CoV-2 neutralizing antibody titers in serum and BAL ( Figures 3A-3F) and B 245 and T cell analyses from PBMCs ( Figures 3G-3I) . 246 AC1 and AC3 induced high SARS-CoV-2 RBD-binding and neutralizing antibody responses from a 247 single dose injection ( Figures 3A and 3E ). Antibody kinetics differed for both candidates, similar to the 248 mouse; AC3 reached near-peak level binding titers at week 4 and neutralizing antibodies leveled of at 249 peak 1 or 2 weeks later. On the other hand, binding antibody was detected for AC1 at week 5, increased 250 until it peaked at week 11. Similar to AC3, kinetics for neutralizing titers trailed the binding ones by one 251 or two weeks. Importantly, neutralizing titer levels remained at peak for at least 11 months (1:1,280 and 252 1:10,240 (or 2,000 and 16,000 IU/ml)) and in range of convalescent titers in patients that underwent ICU 253 admission of 3,016±4,767 IU/mL ( Figure 3B ). Both AC1 animals showed higher neutralizing antibody 254 levels than those immunized with AC3 ( Figure 3A ). Neutralization was further validated and 255 benchmarked by live SARS-CoV-2 plaque neutralization ( Figure 3C ) and VSV-pseudovirus at the 256 Nexelis BMFG and CEPI reference laboratory (Laval, Canada) ( Figure 3D) . A broncho-alveolar lavage 257 was performed at 5 months following immunization and showed detectable levels of RBD-binding IgG, 258

IgA, and neutralizing antibodies for AC1, but not for AC3 ( Figure 3F) . responses were detectable starting on week 4, peaked around week 10 and were still detectable on week 267 44 (month 11) post-vaccination. Higher response was measured in the one of the AC3 animals, which also 268 showed robust memory T cell profile by intracellular staining of PBMCs ( Figures S4B-S4E) . 269

Given the low N-number in this study, these results illustrate the qualitative potential of AC1 and AC3. 270

Based on the superior immunogenicity in mice and (in a limited manner in) macaque, its modestly higher 271 manufacturing yields, and its ability to induce a proportionally more neutralizing response, AC1 was 272 selected as a lead candidate to progress in additional well-powered studies. 4C and 4D). Cross-reactivity of antibodies in the sera harvested on week 9 (pre-challenge, Figure 4E ) and 289

week 14 (4 weeks post-challenge, Figure 4F ) to 4 SARS-CoV-2 variants of concern (Alpha (B.1.17) 290 emerged in UK, Beta (B.1.351) in South Africa, Gamma (P.1) in Brazil and Delta (B.1.617.2) in India) 291 was tested in a pseudovirus neutralization assay. Sera from AC1-treated animals neutralized Alpha variant 292 at same level as the parental SARS-CoV-2 Spike pseudovirus. However, neutralization was reduced by 293 11.3-fold against Beta, 3-5-fold against Gamma and 2-5-fold against Delta, similar in magnitude to the 294 reduction observed in plasma from convalescent patients that were infected with wild type or Alpha-based 295 variants ( Figure S5K ). Importantly, all animals showed some degree of neutralization of all VOCs on 296

week 14 ( Figure 4F ). IFN-γ ELISPOT showed robust cellular response in PBMCs in all AC1 animals by 297

week 7, which were maintained at week 9 ( Figure 4G ). 298

In the unvaccinated control animals, the challenge led to high viral loads in the upper respiratory tract and Lung damage was assessed by CT scan analysis ( Figure 4J ) and no major lesions were observed in the 308 immunized animals. In contrast, control animals presented with larger and more severe lesions in 2 309 animals. Lung draining lymph node activation was analyzed by [ 18 F]-FDG uptake using PET scan and all 310 control animals presented an increase activation after challenge, indicative of SARS-CoV-2 infection 311 ( Figure 4K ). Examples of images obtained by PET scan after challenge from non-vaccinated NHPs are 312 presented ( Figure S6 ). Animals that received AC1 however, showed no change in inflammatory responses 313 upon challenge, most likely due to complete neutralization of the virus and suggestive of sterilizing 314 protection ( Figure 4K ). Additionally, control animals showed a decrease in circulating lymphocyte count 315 on day 2 following viral challenge, which is also observed in COVID-19 patients (Zhu et al., 2020c) , above were analyzed for in vitro neutralization of AAVrh32.33, used in AC1, and serotypes AAV1, 2, 5, 327 8, and 9, which are commonly used in gene therapy studies. Table 1 illustrates AAVrh32.33 neutralizing 328 antibodies developed with slow kinetics and to relatively low levels. Importantly, no cross-reactive 329 neutralizing antibody responses were detected to AAV1, 2, 5, 8, or 9. Furthermore, compared to baseline 330 sample, no significant AAV capsid-specific cellular response was detected in PBMCs collected from 331 animals 4 and 8 weeks after IM AC1 or AC3 injection ( Figure S4F ). 332

AAVCOVID transgene-specific DNA and mRNA analysis of various C57BL/6 tissues of animals that 334 received a single intramuscular injection was performed to establish biodistribution, the persistence of 335 vector genomes, and the kinetics of transgene expression ( Figure 5 ). Previously, an AAVrh32.33 336 expressing a non-self-transgene, when injected intramuscularly in mice, showed declining transgene 337 expression over time that was associated with increasing inflammatory infiltrates at the injection site 338 several weeks after injection (Mays et al., 2009; Mays et al., 2013) . This is in stark contrast to other 339 AAVs expressing the same transgene which led to stable transgene expression and minimal local 340 inflammation (Mays et al., 2009; Mays et al., 2013 ). In the current experiment, C57BL/6 mice were 341 injected with 10 11 gc in the right gastrocnemius muscle. Animals were euthanized 1, 4, 8 and 16 weeks 342 after vaccination and tissues were analyzed for vector genome copies and transgene expression. As 343 observed in Figure 5A , vector genome copies in the injected muscle decreased more than 20-fold from 344

week 1 to week 16. AC3 transgene expression declined similarly. Remarkably, AC1 transgene expression 345 was close to background levels and over 10-fold lower than AC3 expression, possibly due to the different 346 promoter in both candidates ( Figure 5B ). Gene transfer and transduction levels of the contralateral 347 gastrocnemius muscle, liver, and spleen demonstrated 10 to 100-fold less vector DNA at week 1 than 348 measured in the injected muscle with a steady decline of vector DNA and RNA, to undetectable RNA 349 levels by week 16 ( Figure 5C ). 350

In order to address the potential concern that waning yet prolonged exposure to antigen may lead to a 351 desensitizing response, a prime-boost study was performed with 10 10 gc of AC1 and AC3 as prime. 26 352 weeks after prime immunization with AC1, animals were boosted with AAV1-S, an AAV1 capsid to 353 avoid neutralizing anti-AAVrh32.33 antibody interference that encodes a full-length SARS-CoV-2 S 354 (AAV1-S). In comparison to control groups that did not receive a boost, RBD-binding and neutralizing 355 antibody responses were functionally recalled after AAV1-S administration ( Figures 5D and 5E) . Early in 2020, global health and economic vitality was disrupted by the global epidemic of COVID-19. A 359 multitude of vaccine technologies have been pursued following the identification of SARS-CoV-2 as the 360 etiological agent . In a remarkable effort within 12 months, several vaccines were 361 found safe, effective, and have been approved by health regulators in various territories. In the early phase 362 of the rollout, vaccine distribution has been highly uneven across the globe primarily due to economic 363 factors and limiting manufacturing supply. Large scale vaccine campaigns have successfully been 364 mounted in the West, however not without initial, and in some cases remaining, challenges. Once 365 substantial vaccine doses are available for low-and middle-income countries, the logistical needs of 366 current vaccines are expected to complicate and prolong the buildup of population immunity at the 367 needed pace; most vaccines currently available require 2 doses and require some type of cold storage. The 368

need for more and more deployable vaccine options thus remains exceptionally high. Ideally, these 369 options should utilize manufacturing streams distinct from current vaccines, be effective from a single 370 dose, and have minimal to no cold-chain requirement. This need is further amplified due to the 371 uncertainty around emerging SARS-CoV-2 variants and vaccine protection, the durability of protection 372 from current vaccines, and vaccine hesitancy. 373

Here, we describe an AAV-based vaccine candidate AC1 that seeks to address a number of these 374 biological and logistical limitations. AC1, a SARS-CoV-2 Spike antigen and gene-based viral vector 375 vaccine was found protective in nonhuman primates from a single low dose intramuscular injection (Fig.  376 4). Immunogenicity of AC1 and AC3 in mouse and nonhuman primate models further demonstrates 377 potent and durable (up to 11 month) neutralizing antibody responses complemented by strong T-cell 378 immunity from a single dose administration. These characteristics are shared with several other gene-379 based vaccine approaches presented to date likely due to their ability to express the antigen endogenously 380 thus allow for direct antigen presentation. Additionally, AC1 manufacturing leverages an established 381 process at scale currently used in the AAV gene therapy industry (Fig. 1) . Importantly, due to the hardy 382 nature of the AAV capsid, it remains stable and active when stored at room-temperature for a month ( immunogenicity between vaccines, laboratories, and assays. We went to significant length to reference 403 our neutralizing antibody readout and benchmark the levels from AC1 and AC3 to allow for these 404 comparisons. The levels from AC1 are in the upper ranges of convalescence, similar to the levels of 405 patients that survived an ICU stay. AC1, when compared to data in nonhuman primates from other 406 vaccines that later demonstrated protection in humans, provides similar levels of neutralizing antibodies 407 to SARS-CoV-2. Furthermore, using international standards and reference laboratories, AC1 data can 408 directly be compared across comparable studies to vaccine data of other groups. 409

To prevent the need or limit the number of boost administrations, durable protection from a vaccine is 410 desirable. AC1, in mice and nonhuman primates, demonstrates at least for 6 months in mice and 11 411 months in NHP neutralization to be stable at peak levels. germinal centers due to more persistent antigen, may have other benefits as it has been described to lead 427 to expanded antibody repertoire, higher antibody affinity, and a broader array of epitope recognition e.g. particularly when vector was delivered systemically (Nature, 2020). Importantly, for use for 459 immunization of a healthy population, the risk versus benefit for a vaccine is substantially different 460 compared to the use of AAV in a gene therapy setting. Further studies are needed to gauge the safety of 461 AC1 at the established human doses, as a prerequisite to human testing. 462

By design, AC1 was constructed as a gene-based vaccine by incorporating an antigenic transgene into the 463 choice of the specific AAVrh32.33 vaccine-appropriate AAV technology. Here, we were able to confirm 464 these cornerstone attributes on AC1 and AC3, including the seroprevalence ( Figure 1C ), clearance 465 kinetics ( Figures 5A and 5B) , and immunogenicity in mouse and nonhuman primate (Figures 2,3 and 4) . 466

Elegantly, given the divergent structural and serological profile of the AAVrh32.33 compared to the 467 vectors used in gene therapy, no cross-reactivity was observed in nonhuman primate studies, suggesting 468 AC1 immunization would not interfere with possible future AAV gene therapy applications (Table 1, Fig  469   S6 ). AC1 and AC3 however do induce neutralizing antibodies to the AAVrh32.33 capsid, possibly 470 interfering with subsequent AAVCOVID repeat dosing (e.g. boost or variant vaccine). Previously, levels 471 up to 1:320 of AAV8 allowed for an AAV8 re-administration to be performed without inhibition (Greig 472 et al., 2016) . However, these would have to be repeated in the context of AAVrh32.33 and AC1. If repeat 473 administration is needed, one could seek a heterologous prime-boost approach with other viral vector 474 vaccines (e.g. adenoviral vectors) that suffer from a similar limitation. The AAVrh32.33 technology here 475 demonstrates its utility as a preventative vaccine for COVID19, and its unique attributes may be 476 applicable to other pathogens or immunization targets. 477

The World Health Organization has developed early in the pandemic a preferred target product profile for 478 a COVID19 vaccine. These include a single-dose primary series followed by lower frequency booster 479 doses, as well as stability at higher storage temperatures, as these are thought to 'greatly enhance vaccine 480 distribution and availability' (https://www.who.int/publications/m/item/who-target-product-profiles-for-481 covid-19-vaccines). Our studies on AC1 in animal models support its potential to protect from COVID19 482 disease and infection from a single dose immunization. In addition, based on the biology of AAV-based 483 vaccines, the data suggest it may lead to highly durable immunogenicity, possibly reducing the frequency 484 and/or need for repeat dosing. Lastly, given the stability of the AAV capsid and its ssDNA genome, AC1 485 has been shown to be stable at ambient temperature for storage for several weeks. To date, the 486 combination of these key attributes, as specified by the WHO, have not been met by any of the currently 487 Biotherapeutics. RCL is a subcontractor with the CDC Foundation and receives royalties from UpToDate. 570

We worked to ensure sex balance in the selection of non-human subjects. 572

One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science. 573 two doses (10 10 gc and 10 11 gc) of AC1 or AC3, n=20 (10 females and 10 males). 598 (B) Pseudovirus neutralizing titers (EC50international units (IU)/mL) (6 females and 6 males per group). 599

from animals 6 weeks after vaccination with 10 10 gc of AC1 or AC3 and stimulated with peptides 602 spanning SARS-CoV-2 Spike protein for 48h. 603

The dotted lines indicate the lower detection limit of the assays. All data are represented as mean ± SD. The dotted lines indicate the lower detection limit of the assay. 629

See also Figure S4 . 630 

Further information and requests for resources and reagents should be directed to and will be 680 fulfilled by the lead contact, Luk H Vandenberghe (luk_vandenberghe@meei.harvard.edu). 681

Plasmid sequences generated in this study have been deposited to Genbank. AAVCOVID19-1 (AC1): 683

Genbank MW408785 and AAVCOVID19-3 (AC3) GenBank MW408786. 684

All data reported in this paper will be shared by the lead contact upon request. 686

This paper does not report original code. 687

Any additional information required to reanalyze the data reported in this paper is available 688 from the lead contact upon request. 689

All the mouse studies were performed in compliance with the Schepens Eye Research Institute IACUC. 692 C57BL/6 (n=20, 10 males and 10 females) and BALB/c (n=20, 10 males and 10 females) were purchased 693 from Jackson Laboratories. Animals were housed in standard BSL1 facilities, with 12-hour light cycles 694 and free access to regular chow diet and water. 6-9 week-old mice were intramuscularly (right 695 gastrocnemius muscle) treated at 10 10 gc/mouse or 10 11 gc/mouse. Serum samples were obtained by 696 submandibular bleeds for humoral immune response analyses. At necropsy, several tissues were collected 697 for analysis of vector presence and transgene expression. 698

Animal procedures performed in the rhesus macaques were approved by the Institutional Animal Care Cynomolgus macaques were randomly assigned to the two experimental groups. The vaccinated group (n 721 = 6) received a 10 12 gc of AC1 vaccine candidate while control animals (n = 6) received only the diluent. 722

Blood samples were harvested on weeks 0, 1, 2, 4, 5, 6, 7, 8 and 9. Sixty-seven days after immunization, 723 all animals were exposed to a total dose of 10 5 pfu of SARS-CoV-2 virus (hCoV-19/France/ Hospital. Age, sex, and gender identity are unknown. 737

Two AAV-based vaccine candidates were tested: AAVCOVID19-1 (AC1) and AAVCOVID19-3 (AC3) 740 ( Figure 1A ) (GenBank MW408785 and MW408786, respectively). AC1 is an AAVrh32.33 vector that 741 expresses the codon optimized, pre-fusion stabilized (furin cleavage site mutated to G 682 SAS 685 and 742 P 986 P 987 substitutions) full length SARS-CoV-2 Spike protein under the control of an SV40 promoter. 743 AC1 carries a short SV40 polyadenylation signal (poly-A). AC3 is an AAVrh32.33 that carries the 744 secreted S1 subunit of SARS-CoV-2 Spike with the tissue plasminogen activator signal peptide (tPA-SP) 745 whose expression is driven by the CMV promoter. AC3 has two more regulatory elements: a woodchuck 746 hepatitis virus posttranscriptional regulatory element (WPRE) and the bovine growth hormone 747 polyadenylation signal (poly-A). 748

Research-grade, high-titer vectors were produced, purified, and titrated by the MEEI/ SERI Gene Transfer 750

Vector Core (https://www.vdb-lab.org/vector-core/). Small-scale vector preparations were generated by Large-scale manufacturing 761 AAVCOVID candidates were produced at larger scale via standard AAV production processes by 762

Novartis Gene Therapies, following their stablished protocol with only minimal modifications to adjust to 763 the AAVrh32.33 technology. Briefly, AC1 and AC3 were produced via three plasmid transfection (AC1 764 or AC3 ITR-flanked transgene, pKan2/rh32.33 (AAV2 rep and AAVrh32.33 capsid construct), and 765 pALD-X80 adenoviral helper plasmid) in an iCellis500 bioreactor (Pall Biosciences). Following cell lysis 766 and lysate clarification, tangential flow filtration (TFF) was conducted to achieve volume reduction. The 767 TFF retentate was next enriched for AAV particles on a cation exchange chromatography column (BIA 768

Separations, Sartorius). The eluate was concentrated, and buffer exchanged through an additional TFF 769 step, before CsCl ultracentrifugation to separate genome containing versus empty AAV particles. Finally, 770 formulation (buffer: 20 mM tris (pH 8.1 ± 0.1), 1 mM magnesium chloride (MgCl2), 200 mM sodium 771 chloride (NaCl) and 0.005% poloxamer 188) was achieved through TFF before bulk drug substance was 772 filtered. 773

The codon optimized SARS-CoV-2 receptor binding domain (RBD) of AAVCOVID vaccine candidates 775 was used as a target for droplet digital PCR (ddPCR)/real-time PCR (qPCR) quantifications. The 776 sequence was checked for secondary structures using the mfold application of the UNAfold software 777 package (Zuker, 2003) at the PCR annealing temperature and TaqMan buffer salt concentrations.Internal databases and determined to be highly specific for our vaccine candidates. No significant matches were 790 found against the RBD oligonucleotides used. 791

In vitro expression studies 792 10 5 HEK293 cell/well were seeded in 12-well plates (Corning, MA, USA) plates and incubated at 37°C 793 overnight. The following day, cells were transfected with 2 µg of AAVCOVID19-1 (pAC1) and 794 AAVCOVID19-3 (pAC3) plasmids using PEI-Max. Cells were harvested 24 and 72 hours after 795 transfection for mRNA and western blot (WB) expression analyses, respectively. In addition, 5x10 4 HuH7 796 cell/well were seeded in 12-well plates and incubated overnight at 37°C. On the following day, 797 adenovirus 5 WT (Ad5) was added to the cells at a MOI of 20 pfu/cell. 2 hours later, media was removed 798 and cells infected with a MOI of 5x10 5 of AC1 or AC3. Cells were harvested 72 hours later for WB 799

Transfection and transduction samples were also collected for RNA gene expression analyses. Total RNA 801 was extracted via Trizol reagent (Invitrogen) and quantified using a Qubit fluorometer 802 (Invitrogen). 7.5µg of Total RNA was DNase-I treated using the Turbo DNA-free kit (Invitrogen). 803

About 1.4µg of DNase-treated total RNA was set aside for reverse transcription against (-)RT controls 804 using the high capacity cDNA reverse transcription kit (Thermo Fisher). Codon optimized RBD gene 805 expression was assessed against a cells only control using qPCR and normalized to human 18S rRNA 806 gene levels by the delta delta Ct method (Livak and Schmittgen, 2001) . 807

Cell lysates were obtained by diluting cell pellets in NuPAGE™ LDS Sample Buffer (4X) (Thermo 809

Fisher Scientific, Cat# NP0007) and incubating at 99°C for 5 minutes,, separated by electrophoresis in 810 (OD) at 450 nm was measured using a Biotek Synergy H1 plate reader. The titer was the reciprocal of the 835 highest dilution with absorbance values higher than four times the average of the negative control wells. 836

For mouse serum SARS-CoV-2 RBD-specific antibody isotyping, the same ELISA was performed but 837 using the secondary antibodies from SBA Clonotyping System-HRP kit (SouthernBiotech, 5300-05, 838 RRID:AB_2796080) diluted accordingly to manufacturer's instructions. 839

Cynomolgus macaque samples were screened for IgG to SARS-CoV-2 antigens using a commercially 840 available multiplexed immunoassay developed by Mesoscale Discovery (MSD,Rockville, MD) as 841 previously described (Johnson et al., 2020b) . Briefly, antigens were spotted at 200−400 μg/mL in a 842

proprietary buffer, washed, dried and packaged for further use (MSD® SARS-CoV2 Plate 2). Then, 843 plates were blocked with MSD Blocker A and then incubated with reference standard, controls and 844 samples diluted 1:500 and 1:5000 in diluent buffer. After incubation, a detection antibody was added 845 (MSD SULFO-TAGTM Anti-Human IgG Antibody) followed by the MSD GOLDTM Read Buffer B. 846

Plates were read using a MESO QuickPlex SQ 120MM Reader. Results were expressed as arbitrary units 847

The MSD pseudo-neutralization assay was used to measure antibodies neutralizing the binding of the 849 spike protein to the ACE2 receptor in cynomolgus samples. Plates were blocked and washed as above, 850 assay calibrator (COVID-19 neutralizing antibody; monoclonal antibody against S protein; 200 μg/mL), 851 control sera and test sera samples diluted 1:10 and 1:100 in assay diluent were added to the plates. 852

Following incubation of the plates, a 0.25 μg/mL solution of MSD SULFO-TAGTM conjugated ACE-2 853 was added and the plates were read as above. Electro-chemioluminescence (ECL) signal was recorded 854 and results expressed as 1/ECL. 855

Lenti-SARS2 was produced based on a published protocol (Crawford et al., 2020) . Specifically, 50% 857 confluent HEK293T cells were seeded 24 hours prior to transfection in 15 cm plates. The next day, 18 858 µg/plate of psPAX2, 9 µg/plate of pCMV-SARS2-Spike (WT or VOC) and 29 µg/plate of pCMV-Lenti-859

Luc plasmids were mixed in 3.6 mL/plate of Opti-MEM™ I Reduced Serum media (Gibco, Cat# 860 31985070) along with 144 µL of PEI Max 40K (1 mg/mL, pH: 6.9-7.1) and mixed thoroughly. The 861 mixture was incubated for 20 minutes at room temperature. Media on cells was aspirated and serum-free 862 DMEM was added to the cells. After 20 mins, the DNA-PEI mixture was added dropwise to the plate and 863 incubated overnight at 37°C with 5% CO 2 . The next day, media was replaced with DMEM with 10% 864 FBS. After 48 hours, the media was collected in a 50 mL conical and centrifuged at 4,000 rpm at 4°C for 865 5 minutes to remove cell debris. The supernatant was collected and filtered through 0.45 µm filter, 866 aliquoted and stored at -80°C. 867

For titration of the pseudovirus, HEK293T cells expressing ACE2 were seeded at 1.5x10 4 cells/well in 868 poly-L-Lysine (0.01%) coated 96-well black plates (Thermo Fisher Scientific, Cat# 3904) one day before 869 titration. On the next day, the media was changed to 50 µL DMEM+10%FBS containing filtered 

HEK293T cells expressing ACE2 were seeded at 1.5x10 4 cells/well in poly-L-Lysine (0.01%) coated 96-882 well black plates. The following day, 50µL of DMEM+10% FBS media containing Hexadimethrine 883 bromide (final concentration 10 µg/mL) was added to the cells. Serum samples were heat-inactivated at 884 56°C for 1 hour. Serum samples were then serially diluted (2-fold) for 10 dilutions in DMEM with 10% 885 FBS with initial dilution of 1:40 for mouse serum and 1:10 dilution for NHP serum. Thereafter, Lenti-886 SARS2 pseudovirus was added to each dilution and incubated at 37°C for 45 minuntes. The serum and 887 virus mixture was added to the cells and incubated at 37°C with 5% CO2 for 48 hours. An anti-SARS-888

CoV-2 Spike monoclonal neutralizing antibody (GenScript, Cat# A02055) was used as a positive control. 889 Splenocytes were obtained by grinding murine spleens with 100 μm cell strainers, followed by treatment 915

with Ammonium Chloride-Potassium (ACK) lysis buffer (Gibco) to lyse the red blood cells. The isolated 916 cells were then suspended in complete RPMI-1640 medium (Gibco) supplemented with 10% FBS and 917 counted for the following experiments. 918 IFN-γ and IL-4 ELISPOT for mice was measured as previously described . Briefly, 919 96-well PVDF plates (Millipore) were pre-coated with 10 μg/ml anti-mouse IFN-γ ELISPOT capture 920 antibody (BD Biosciences Cat# 551881, RRID:AB_2868948) or 4 μg/ml anti-mouse IL-4 ELISPOT 921 capture antibody (BD Biosciences Cat# 551878, RRID:AB_2336921) at 4°C overnight, and then blocked 922 with complete RPMI-1640 medium for 3 hours at 37°C. One million of freshly isolated splenocytes were 923 seeded into the precoated plates and stimulated with S1 and S2 peptides pools (GenScript) with a final 924 concentration of 1 μg/ml of each peptide diluted in RPMI-1640 supplemented with 10% FBS and 925 incubated for 48 hours at 37°C with 5% CO 2 . Each peptide pool, consisting of 15-mers peptides 926 overlapping by 10 amino acids, spanning the entire SARS-CoV-2 Spike protein S1 or S2 subunits. 

Rhesus macaque peripheral blood T cell responses against AC1, AC3 and the AAVrh32.33 capsid were 938 measured by interferon gamma (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT) assays according 939 to previously published methods (Calcedo et al., 2018) . Peptide libraries specific for AAVrh32.33 capsid 940 as well as the AC1 and AC3 transgenes were generated (15-mers with a 10 amino acid overlap with the 941 preceding peptide; Mimotopes, Australia). Peptides were dissolved in dimethyl sulfoxide (DMSO) at a 942 concentration of 100 mg/mL, pooled, aliquoted and stored at -80°C. They were used at a final 943 concentration in the assay of approximately 2 µg/mL. The positive response criteria for the IFN-γ 944 ELISPOT was greater than 55 spot forming units (SFU) per million cells and at least three times greater 945 than the negative control values. quantifying serum and BAL urea levels using the Urea Assay Kit (abcam, ab83362) as described 960

previously (Kaulbach et al., 1993) . 961 PBMC stimulation and flow cytometry 962 purposes of visualization. A sequence identity matrix was computed, and the resultant table was used to 1108 annotate the phylogeny by percent identity. 1109

GraphPad Prism 8 was used for graph preparation and statistical analysis. Data were represented as mean 1112 ± standard deviation (SD). Groups were compared between them by One-way ANOVA and Tukey's tests 1113 in studies with more than two groups and n≥10, and Kruskal Wallis and Dunn's testes were used if n<10. 1114

Two groups were compared between them using Student's t test (independent samples, n≥10), Mann 1115

Whitney's U (independent samples, n<10) or Wilcoxon Signed Rank test (paired samples, n<10). 1116

Pearson's correlation coefficient was calculated to assess correlation. 1117

clone EH12.2H7, BioLegend Cat# 329919, 988 RRID:AB_10900818), CD14 BV510 (clone M5E2, BioLegend Cat# 301842, RRID:AB_2561946) and

clone M5E2, BioLegend Cat# 301819, RRID:AB_493694), CD16 BV510

RRID:AB_2562085) and APC-Cy7 (clone 3G8, BioLegend Cat# 302017, 991 RRID:AB_314217), CD20 BV510 (clone 2H7, BioLegend Cat# 302339, RRID:AB_2561721) and

BV650 (clone 2H7, BioLegend Cat# 302335, RRID:AB_11218609), CD69 BV605 (clone FN50

994 RRID:AB_2561576), CD4 BUV661 (clone SK3, BD Biosciences Cat# 612962

CD95 BUV737 (clone DX2, BD Biosciences Cat# 612790, RRID:AB_2870117)

RRID:AB_2870199), KI67 BV786 (clone B56

RRID:AB_2732007), IL2 PE (clone MQ1-17H12, BD Biosciences Cat# 554566, 998 RRID:AB_395483), IFNγ BV750 (clone B27

BUV805 (clone SP34-2, BD Biosciences Cat# 742053, RRID:AB_2871342)

RRID:AB_1645453), CD3 APC-Cy7 (clone SP34-2

RRID:AB_396863), IgM PECy5 (clone G20-127, BD Biosciences Cat# 1002 551079, RRID:AB_394036), CD27 BV421 (clone M-T271, BD Biosciences Cat# 562513, 1003 RRID:AB_11153497), HLA-DR BV605

CXCR3 AF488 (clone 1C6

RRID:AB_2717183)

RRID:AB_953657)

RRID:AB_11218511), TNFα PE-Cy7 (clone Mab11

RRID:AB_1257208), and polyclonal anti-IgD PE Tx Red 1010

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 1120 variants in humans

Safety and Immunogenicity of SARS-CoV-2 1123 mRNA-1273 Vaccine in Older Adults

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Thermal Stability as a Determinant of AAV Serotype Identity

Safety and durability of effect of contralateral-eye administration of 1132 AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on 1133 phase 1 trial

Association of Sex, Age, and 1135 Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis

Assessment of Humoral, Innate, and T-Cell Immune 1138 Responses to Adeno-Associated Virus Vectors

Worldwide epidemiology of 1140 neutralizing antibodies to adeno-associated viruses

Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects 1143 against SARS-CoV-2-Mediated Pathogenesis in Mice

Slow Delivery Immunization Enhances HIV Neutralizing 1146

Responses via Modulation of Immunodominance

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in 1153 Nonhuman Primates

Detection of 2019 novel coronavirus (2019-nCoV) by real-time 1156 RT-PCR. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable 1157 disease bulletin 25

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 1160

Spike Protein for Neutralization Assays

Obesity population at risk of COVID-19 complications. Global health, 1162 epidemiology and genomics 5

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

ProtTest 3: fast selection of best-fit models 1167 of protein evolution

An 1169 adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus 1170 macaques

Safety and immunogenicity of a candidate Middle East respiratory syndrome 1173 coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1174 1 trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against 1177 SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Evolution of antibody immunity to SARS-CoV-2

Adeno-associated viruses are widely disseminated in human tissues

Adeno-associated virus-mediated gene transfer to nonhuman primate liver can 1186 elicit destructive transgene-specific T cell responses

Multiple SARS-CoV-2 variants escape neutralization 1189 by vaccine-induced humoral immunity

Evaluation of the immunogenicity of prime-boost 1192 vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. 1193 NPJ Vaccines 5

Intramuscular administration of AAV overcomes pre-existing 1196 neutralizing antibodies in rhesus macaques

NVX-CoV2373 vaccine protects cynomolgus macaque upper 1199 and lower airways against SARS-CoV-2 challenge

A simple, fast, and accurate algorithm to estimate large phylogenies 1201 by maximum likelihood

A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against 1204 SARS-CoV-2

Gene Therapy

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report. The

Immunological surrogate endpoints of COVID-2019 1210 vaccines: the evidence we have versus the evidence we need

The Transcription Factor T-bet Resolves Memory B Cell 1214 Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans

Evaluation of a novel multiplexed assay for determining IgG levels and 1218 functional activity to SARS-CoV-2

Advancements in molecular 1221 design and bioprocessing of recombinant adeno-associated virus gene delivery vectors using the insect-1222 cell baculovirus expression platform

Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice 1225 and non-human primates

Estimation of nasal 1227 epithelial lining fluid using urea as a marker

T-bet+ B cells are induced by human viral infections and dominate 1230 the HIV gp140 response

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate 1233 for Middle East respiratory syndrome: an open-label, phase 1 trial

Phase 1 Assessment of the Safety and Immunogenicity of an 1236 mRNA-Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

MEGA X: Molecular Evolutionary Genetics 1238 Analysis across Computing Platforms

REPuter: 1240 the manifold applications of repeat analysis on a genomic scale

3'-minor groove binder-DNA probes increase sequence specificity at PCR 1243 extension temperatures

An improved general amino acid replacement matrix

Antibody-dependent enhancement and 1247 SARS-CoV-2 vaccines and therapies

Clinical and virological data of the first cases of 1250 COVID-19 in Europe: a case series

The 1252 Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Novel 1255 AAV-based genetic vaccines encoding truncated dengue virus envelope proteins elicit humoral immune 1256 responses in mice

A new genetic 1258 vaccine platform based on an adeno-associated virus isolated from a rhesus macaque

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Analysis of relative gene expression data using real-time 1263 quantitative PCR and the 2(-Delta Delta C(T)) Method

Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale

Safety and immunogenicity of an rAd26 and 1269 rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-1270 randomised phase 1/2 studies from Russia

Hydroxychloroquine use against SARS-CoV-2 infection in non-1273 human primates

Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates 1276 Achieved by Sequential Administration of AAV5 ch and AAV1. Molecular therapy : the journal of the 1277 American Society of Gene Therapy 25

DINAMelt web server for nucleic acid melting prediction

UNAFold: software for nucleic acid folding and hybridization

A SARS DNA vaccine induces neutralizing antibody and cellular immune 1284 responses in healthy adults in a Phase I clinical trial

Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector 1287 encoded proteins

Mapping the structural determinants responsible for enhanced T cell 1290 activation to the immunogenic adeno-associated virus capsid from isolate rhesus 32

Correlates of protection against SARS-CoV-2 in rhesus macaques

Safety & immunogenicity of tgAAC09, a recombinant adeno-1297 associated virus type 2 HIV-1 subtype C vaccine in India

A phase 1 study to evaluate the safety and immunogenicity of a 1301 recombinant HIV type 1 subtype C adeno-associated virus vaccine

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. The New 1305 England journal of medicine 377

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus 1308 macaques

Overcoming the Host Immune Response to Adeno-Associated Virus 1310

Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape

Safety and immunogenicity of an anti-Middle East respiratory syndrome 1314 coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. The Lancet Infectious

Evaluation of COVID-19 vaccination strategies with a delayed second dose

Development of potency, breadth and 1320 resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. bioRxiv

A synthetic consensus anti-spike protein DNA vaccine induces 1324 protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates

High-dose AAV gene therapy deaths

AAV Vectors Vaccines Against Infectious Diseases

V367F 1329 mutation in SARS-CoV-2 spike RBD emerging during the early transmission phase enhances viral 1330 infectivity through increased human ACE2 receptor binding affinity

AAV-ID: A Rapid and Robust Assay for Batch-to-Batch 1333 Consistency Evaluation of AAV Preparations

Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19)

Intradermal-delivered DNA vaccine provides anamnestic protection in a 1339 rhesus macaque SARS-CoV-2 challenge model

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody 1342 neutralization

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Comparative analysis of adeno-associated virus capsid stability and 1348 dynamics

Manufacturing of 1350 recombinant adeno-associated viruses using mammalian expression platforms

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against 1354 Covid-19

Adeno-associated Virus as a Mammalian DNA 1356 Vector

A single-dose live-attenuated 1359 YF17D-vectored SARS-CoV-2 vaccine candidate

Quantitative and Digital Droplet-Based AAV 1361

Radiological findings 1363 from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Clustal Omega for making accurate alignments of many protein 1366 sequences

Intramuscular administration of AAV1-lipoprotein lipase S447X lowers 1369 triglycerides in lipoprotein lipase-deficient patients. Arteriosclerosis, thrombosis, and vascular biology

Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology 1373 on challenge with the SARS virus

ChAdOx1 nCoV-19 vaccine 1379 prevents SARS-CoV-2 pneumonia in rhesus macaques

AAV as an immunogen

Tailoring the AAV vector capsid for gene therapy

A phase 2 study to evaluate the safety and immunogenicity of a 1385 recombinant HIV type 1 vaccine based on adeno-associated virus

BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine 1391 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South 1392 Africa, and the UK

Structure, Function, and 1394 Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

A trivalent 1401 HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey

Durability of Responses after SARS-CoV-2 1405 mRNA-1273 Vaccination

Virological assessment of hospitalized patients with COVID-1408 2019

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

1413 (2021a). Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in 1414 mice

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Induction of robust immune responses against human immunodeficiency virus 1420 is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Digital Photon Counting PET/CT: The Physics Powering Precision Nuclear Medicine

A Thermostable mRNA Vaccine against COVID-19

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic 1435 Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy 1438 adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: 1442 a dose-escalation, open-label, non-randomised, first-in-human trial

Novel 1444 adenoassociated virusbased genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral 1445 immune responses in mice

Clinical characteristics of 1447 3062 COVID-19 patients: A meta-analysis

Mfold web server for nucleic acid folding and hybridization prediction. Nucleic acids 1449 research 31

Cells without serum and virus were used as negative control. After 48 hours, cells were lysed and 890 luciferase measured as described above. Neutralizing antibody titers or 50% inhibitory concentration in 891 the serum sample (EC50 or ID50) were calculated as the reciprocal of the highest dilution showing less 892 RLU signal than half of the average RLU (maximum infectivity) of Virus Control group (cells + virus, 893 without serum). Pseudovirus neutralizing titers were converted to international units (IU)/mL with the 894 NIBSC 20/136 WHO International Standard. 895

Depending on the volume available, mouse or NHP sera were serially diluted two-fold from an initial 897 dilution of either 1:12.5 or 1:25 for ten dilutions in Dulbecco's Phosphate Buffered Saline (DPBS, 898 Gibco). Each dilution was incubated at 37℃ and 5% CO2 for 1 hour with an equal volume of 1000 plaque 899 forming units/ml (PFU/ml) of SARS-CoV-2 (isolate USA-WA1/2020) diluted in DMEM (Gibco) 900 containing 2% fetal bovine serum (Gibco) and antibiotic-antimycotic (Gibco). Controls included DMEM 901 containing 2% fetal bovine serum (Gibco) and antibiotic-antimycotic (Gibco) only as a negative control, 902 1000 PFU/ml SARS-CoV-2 incubated with DPBS, and 1000 PFU/ml SARS-CoV-2 incubated with 903 DMEM. Two hundred microliters of each dilution or control were added to confluent monolayers of NR-904 596 Vero E6 cells in triplicate and incubated for 1 hour at 37°C and 5% CO2. The plates were gently 905 rocked every 5-10 minutes to prevent monolayer drying. The monolayers were then overlaid with a 1:1 906 mixture of 2.5% Avicel® RC-591 microcrystalline cellulose and carboxymethylcellulose sodium 907 (DuPont Nutrition & Biosciences) and 2X Modified Eagle Medium (Temin's modification, Gibco) 908 supplemented with 2X antibiotic-antimycotic (Gibco), 2X GlutaMAX (Gibco) and 10% fetal bovine 909 serum (Gibco). Plates were incubated at 37°C and 5% CO2 for 2 days. The monolayers were fixed with 910 10% neutral buffered formalin and stained with 0.2% aqueous Gentian Violet (RICCA Chemicals) in 911 10% neutral buffered formalin for 30 minutes, followed by rinsing and plaque counting. The half 912 maximal inhibitory concentrations (EC50 or ID50) were calculated using GraphPad Prism 8. 913

Cryopreserved peripheral blood mononuclear cells (PBMC) were thawed and rested overnight in sterile 963 R10 media (RPMI 1640, Corning), supplemented with 10% fetal bovine serum (Gemini Bio-Products), 964Penicillin/Streptomycin and L-Glutamine; plus 10 U/mL DNAse I (Roche Life Sciences) at 37°C, 5% 965 CO2 and 95% humidity incubation conditions. PBMC were stimulated at 200 ul final volume in sterile 966 source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-1036 paris.pdf?sfvrsn=3662fcb6_2). The limit of detection was estimated to be 2.87 log 10 copies of SARS-1037CoV-2 sgRNA per mL and the limit of quantification was estimated to be 3.87 log 10 copies per mL. Besides, regions with FDG uptake (lung, lung draining lymph nodes and spleen) were also defined for 1059 quantification of SUV parameters, including SUVmean, SUVmax. 1060

NAb responses against AAV1, AAV2, AAV5, AAV8, AAV9 and AAVrh32.33 capsids were measured in 1062 serum using an in vitro HEK293 cell-based assay and LacZ expressing vectors (Vector Core Laboratory, 1063University of Pennsylvania, Philadelphia, PA) as previously described (Calcedo et al., 2018) . The NAb 1064 titer values are reported as the reciprocal of the highest serum dilution at which AAV transduction is 1065 reduced 50% compared to the negative control. The limit of detection of the assay was a 1:5 serum 1066 dilution. 1067

Tissue collection was segregated for genomic DNA (gDNA) or total RNA work by QIASymphony Capacity cDNA Reverse Transcription Kit (Thermo Fisher). For ddPCR (gDNA or cDNA) or qPCR 1082 (cDNA), 2 L of processed nucleic acids were used for quantification using Bio-Rad or Applied 1083Biosystems reagents, respectively, in 20 L reactions using default amplification parameters without an 1084 UNG incubation step. All the studies included negative control (PBS) groups for comparison. The 1085 significantly small variance of multiple technical replicates in ddPCR justified the use of a single 1086 technical replicate per sample and no less than three biological replicates per group, gender, or time point. 1087 coRBD signal for ddPCR and vector biodistribution (gDNA) was multiplexed and normalized against the 1088 mouse transferrin receptor (Tfrc) gene TaqMan assay using a commercial preparation validated for 1089 copy number variation analysis (Thermo Fisher Scientific). Likewise, coRBD signal for ddPCR and gene 1090 expression analysis was multiplexed and normalized against the mouse GAPDH gene, also using a 1091 commercial preparation of the reference assay (Thermo Fisher Scientific). Target and reference 1092 oligonucleotide probes are tagged with different fluorophores at the 5'-end which allows efficient signal 1093 stratification. For qPCR, coRBD and mGAPDH TaqMan assays were run separately to minimize 1094 competitive PCR multiplexing issues prior to analysis and delta delta Ct normalization (Livak and 1095 Schmittgen, 2001). The limit of detection of the assay was 10 copies/reaction, therefore, wells with less 1096 than 10 copies were considered negative. 1097

First, fourteen representative AAV capsid sequences were aligned by Clustal Omega (Sievers and 1099 Higgins, 2018) . Substitution models and model parameters were statistically compared (120 in total) 1100 through ProtTest3 (Darriba et al., 2011; Guindon and Gascuel, 2003) , and the Le, Gascuel Model (Le and 1101Gascuel, 2008) was selected based on the Aikake Information Criterion (AIC). Additionally, amino acid 1102 frequencies were determined empirically through the alignment (+F parameter) and evolutionary rates 1103 among sites were allowed to vary within five categories by modeling variability with a discrete Gamma 1104 distribution (+G parameter), again selected through AIC. A maximum-likelihood approach was then used 1105 to infer the evolutionary relationships among the included sequences using MEGA X (Kumar et al., 2018 (Kumar et al., ) 1106 and the resultant phylogeny rooted along the midpoint of the branch between AAV4 and AAV5 for 1107